Insmed Incorporated (INSM)
NASDAQ$76.55
Market Cap
$13.86B
Sector
Healthcare
Industry
Medical—Pharmaceuticals
Rank in Sector
647 of 924
Rank in Industry
4 of 6
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
INSM Insider Trading Activity
INSM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $109,509,299 | 73 | 100 |
Related Transactions
| Wise John Drayton | Chief Commercial Officer | 0 | $0 | 7 | $2.06M | $-2.06M |
| Adsett Roger | Chief Operating Officer | 0 | $0 | 9 | $8.12M | $-8.12M |
| Smith Michael Alexander | Chief Legal Officer | 0 | $0 | 8 | $12.76M | $-12.76M |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 0 | $0 | 11 | $17.71M | $-17.71M |
| Bonstein Sara | Chief Financial Officer | 0 | $0 | 10 | $17.97M | $-17.97M |
| Lewis William | Chair and CEO | 0 | $0 | 13 | $22.81M | $-22.81M |
| Flammer Martina M.D. | Chief Medical Officer | 0 | $0 | 15 | $28.09M | $-28.09M |
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a …
Insider Activity of Insmed Incorporated
Over the last 12 months, insiders at Insmed Incorporated have bought $0 and sold $109.51M worth of Insmed Incorporated stock.
On average, over the past 5 years, insiders at Insmed Incorporated have bought $720,998 and sold $31.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $385,800 was made by SHAROKY MELVIN MD (director) on 2023‑05‑15.
List of Insider Buy and Sell Transactions, Insmed Incorporated
| 2025-03-03 | Sale | Lewis William | Chair and CEO | 8,075 0.0045% | $76.38 | $616,783 | -1.64% | |
| 2025-03-03 | Sale | Lewis William | Chair and CEO | 25,580 0.0145% | $77.79 | $1.99M | -1.64% | |
| 2025-02-18 | Sale | Lewis William | Chair and CEO | 25,580 0.0146% | $81.03 | $2.07M | -4.76% | |
| 2025-02-18 | Sale | Bonstein Sara | Chief Financial Officer | 18,322 0.0104% | $80.31 | $1.47M | -4.76% | |
| 2025-02-12 | Sale | Bonstein Sara | Chief Financial Officer | 5,019 0.0028% | $80.00 | $401,520 | -2.44% | |
| 2025-02-11 | Sale | Bonstein Sara | Chief Financial Officer | 13,302 0.0076% | $80.00 | $1.06M | -1.87% | |
| 2025-02-10 | Sale | Adsett Roger | Chief Operating Officer | 42,975 0.0237% | $78.61 | $3.38M | +0.70% | |
| 2025-02-10 | Sale | Flammer Martina M.D. | Chief Medical Officer | 37,828 0.0208% | $78.61 | $2.97M | +0.70% | |
| 2025-02-07 | Sale | Adsett Roger | Chief Operating Officer | 100 <0.0001% | $79.57 | $7,957 | -1.95% | |
| 2025-02-07 | Sale | Flammer Martina M.D. | Chief Medical Officer | 60 <0.0001% | $79.59 | $4,775 | -1.95% | |
| 2025-02-07 | Sale | Wise John Drayton | Chief Commercial Officer | 10 <0.0001% | $78.91 | $789 | -1.95% | |
| 2025-02-06 | Sale | Lewis William | Chair and CEO | 79,350 0.0441% | $80.90 | $6.42M | -2.61% | |
| 2025-02-06 | Sale | Adsett Roger | Chief Operating Officer | 45,605 0.0253% | $80.90 | $3.69M | -2.61% | |
| 2025-02-06 | Sale | Bonstein Sara | Chief Financial Officer | 28,390 0.0158% | $80.90 | $2.3M | -2.61% | |
| 2025-02-06 | Sale | Flammer Martina M.D. | Chief Medical Officer | 33,055 0.0184% | $80.90 | $2.67M | -2.61% | |
| 2025-02-06 | Sale | Wise John Drayton | Chief Commercial Officer | 7,910 0.0044% | $80.90 | $639,919 | -2.61% | |
| 2025-02-06 | Sale | Schaeffer Orlov S Nicole | Chief People Strategy Officer | 23,500 0.013% | $80.90 | $1.9M | -2.61% | |
| 2025-02-06 | Sale | Smith Michael Alexander | Chief Legal Officer | 20,650 0.0115% | $80.90 | $1.67M | -2.61% | |
| 2025-02-03 | Sale | Lewis William | Chair and CEO | 25,580 0.0146% | $77.94 | $1.99M | +1.55% | |
| 2025-01-30 | Sale | Schaeffer Orlov S Nicole | Chief People Strategy Officer | 91,140 0.0523% | $80.00 | $7.29M | +3.37% |
Total: 303
*Gray background shows transactions not older than one year
Insider Historical Profitability
14.35%
| Lewis William | Chair and CEO | 233924 0.1292% | $17.91M | 7 | 36 | +45.59% |
| Adsett Roger | Chief Operating Officer | 146082 0.0807% | $11.18M | 1 | 24 | +43.16% |
| ALLAN GEOFFREY | President, CEO and Chairman | 1166464 0.6445% | $89.29M | 1 | 0 | +1.39% |
| ENGELSEN STEINAR J | director | 320802 0.1772% | $24.56M | 9 | 0 | +12.65% |
| SHAROKY MELVIN MD | director | 298615 0.165% | $22.86M | 13 | 7 | +30.83% |
*Gray background shows insiders who have made transactions during last year
INSM Institutional Investors: Active Positions
| Increased Positions | 250 | +58.14% | 20M | +10.37% |
| Decreased Positions | 193 | -44.88% | 15M | -8.09% |
| New Positions | 72 | New | 4M | New |
| Sold Out Positions | 51 | Sold Out | 3M | Sold Out |
| Total Postitions | 487 | +13.26% | 193M | +2.29% |
INSM Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $1.49M | 10.07% | 18.22M | +1M | +6.28% | 2024-12-31 |
| Blackrock, Inc. | $1.31M | 8.86% | 16.03M | +1M | +7.1% | 2024-12-31 |
| Darwin Global Management, Ltd. | $1.06M | 7.16% | 12.96M | +2M | +23.47% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $1.04M | 7.02% | 12.7M | +123,429 | +0.98% | 2024-12-31 |
| Capital International Investors | $580,391.00 | 3.93% | 7.12M | +593,206 | +9.09% | 2024-12-31 |
| State Street Corp | $497,957.00 | 3.37% | 6.11M | -72,077 | -1.17% | 2024-12-31 |
| Baker Bros. Advisors Lp | $408,310.00 | 2.77% | 5.01M | +590,945 | +13.38% | 2024-12-31 |
| Fmr Llc | $396,027.00 | 2.68% | 4.86M | -2M | -32.47% | 2024-12-31 |
| Geode Capital Management, Llc | $333,307.00 | 2.26% | 4.09M | +273,759 | +7.18% | 2024-12-31 |
| Jpmorgan Chase & Co | $267,994.00 | 1.82% | 3.29M | -20,098 | -0.61% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.